中文名 | PK11007 |
英文名 | PK11007 |
别名 | 5-氯-2-((4-氟苄基)磺酰基)-N-(5-甲基-1,3,4-噻二唑-2-基)嘧啶-4-甲酰胺 |
英文别名 | PK11007 PK-11007 PK 11007 5-Chloro-2-((4-fluorobenzyl)sulfonyl)-N-(5-methyl-1,3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide 5-chloro-2-[(4-fluorophenyl)methylsulfonyl]-N-(5-methyl-1,3,4-thiadiazol-2-yl)pyrimidine-4-carboxamide 5-Chloro-2-[[(4-fluorophenyl)methyl]sulfonyl]-N-(5-methyl-1,3,4-thiadiazol-2-yl)-4-pyrimidinecarboxamide 4-Pyrimidinecarboxamide,5-chloro-2-[[(4-fluorophenyl)methyl]sulfonyl]-N-(5-methyl-1,3,4-thiadiazol-2-yl)- |
CAS | 874146-69-7 |
化学式 | C15H11ClFN5O3S2 |
分子量 | 427.8609432 |
溶解度 | 溶于DMSO |
存储条件 | 2-8°C |
参考资料 展开查看 | 1: Duffy MJ, Synnott NC, Crown J. Mutant p53 in breast cancer: potential as atherapeutic target and biomarker. Breast Cancer Res Treat. 2018 Mar 21. doi:10.1007/s10549-018-4753-7. [Epub ahead of print] Review. PubMed PMID: 29564741. 2: Synnott NC, Bauer MR, Madden S, Murray A, Klinger R, O'Donovan N, O'Connor D,Gallagher WM, Crown J, Fersht AR, Duffy MJ. Mutant p53 as a therapeutic targetfor the treatment of triple-negative breast cancer: Preclinical investigationwith the anti-p53 drug, PK11007. Cancer Lett. 2018 Feb 1;414:99-106. doi:10.1016/j.canlet.2017.09.053. Epub 2017 Oct 22. PubMed PMID: 29069577. 3: Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment.Eur J Cancer. 2017 Sep;83:258-265. doi: 10.1016/j.ejca.2017.06.023. Epub 2017 Jul28. Review. PubMed PMID: 28756138. 4: Bauer MR, Joerger AC, Fersht AR. 2-Sulfonylpyrimidines: Mild alkylating agentswith anticancer activity toward p53-compromised cells. Proc Natl Acad Sci U S A.2016 Sep 6;113(36):E5271-80. doi: 10.1073/pnas.1610421113. Epub 2016 Aug 22.PubMed PMID: 27551077; PubMed Central PMCID: PMC5018792. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.337 ml | 11.686 ml | 23.372 ml |
5 mM | 0.467 ml | 2.337 ml | 4.674 ml |
10 mM | 0.234 ml | 1.169 ml | 2.337 ml |
5 mM | 0.047 ml | 0.234 ml | 0.467 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!